Core Laboratories (CLB) Non-Current Deferred Tax Liability (2022 - 2026)

Core Laboratories' Non-Current Deferred Tax Liability history runs 5 years deep, the most recent figure standing at $8.1 million for Q1 2026.

• On a quarterly basis, Non-Current Deferred Tax Liability fell 18.48% year-over-year to $8.1 million in Q1 2026; TTM through Mar 2026 was $8.1 million, a 18.48% decrease from a year earlier, with the FY2025 full-year figure at $8.0 million, down 11.81% from the prior year.
• Non-Current Deferred Tax Liability grew to $8.1 million in Q1 2026 per CLB's latest filing, from $8.0 million in the prior quarter.
• Across five years, Non-Current Deferred Tax Liability topped out at $22.9 million in Q4 2022 and bottomed at $8.0 million in Q4 2025.
• The 5-year median for Non-Current Deferred Tax Liability is $11.9 million (2023), against an average of $12.0 million.
• Across the five-year window, Non-Current Deferred Tax Liability slumped 44.5% in 2023 and rose 14.01% in 2024, its largest moves.
• Year by year, Non-Current Deferred Tax Liability stood at $22.9 million in 2022, then sank by 44.5% to $12.7 million in 2023, then fell by 28.6% to $9.1 million in 2024, then retreated by 11.81% to $8.0 million in 2025, then gained by 0.98% to $8.1 million in 2026.
• Per Business Quant, the three latest CLB Non-Current Deferred Tax Liability figures stand at $8.1 million (Q1 2026), $8.0 million (Q4 2025), and $10.1 million (Q3 2025).